science
Trump Administration Opens Section 301 Probe Into German Drug Pricing
The investigation follows Germany's proposal to pay less for U.S.-developed medicines. It will run through the fall with a public hearing set for Sept. 22. The move echoes an earlier tariff threat that led the United Kingdom to raise payments.
Jun 26, 7:00 AM·1m read1 source
Fox NewsAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
The Trump administration launched a Section 301 investigation into German drug pricing on June 18. U.S. Trade Representative Jamieson Greer announced the step after Germany proposed paying less for medicines developed in the United States.
Fox News reported that Germany already pays less than the United States for American-made drugs. For the most expensive products, Americans pay four times more than Germans. It takes U.S. pharmaceutical companies an average of $2.7 billion to bring a new drug to market.
The probe will continue into the fall. A public hearing is scheduled for Sept. 22. If the administration determines Germany acted unfairly, it could impose tariffs. The administration also expanded the TrumpRx prescription drug discount program to more than 800 medications.
Until earlier this year the United Kingdom paid far less for American medicines. After the Trump administration threatened tariffs, the United Kingdom agreed to pay more.
